Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The shipment was arranged under the umbrella of BP8’s Sales Cooperation Agreement with PT. Kebula Raya Bestari, which will see the latter handle logistics and supply arrangements for the product.

MSC plans to use the product – to be delivered as 60 metric tonnes of Indonesian seaweed biomass – to make carrageenan, an additive used to thicken and stabilise food products.

BP8’s managing director, Matthew Leonard, said achieving the first shipment indicated the partnership with PT. Kebula Raya Bestari was on the right track.

“We are pleased to announce our first shipment under the Sales Cooperation Agreement with Kebula, which demonstrates the practical progress of our strategic partnership,” BP8’s boss explained in a market release today.

“Kebula’s role in managing logistics is enabling BP8 to efficiently connect Indonesian seaweed supply with international customers like MSC.”

More market news

Trims: An RBA cut was locked. Beijing’s identical chop spotlights larger macro forces

Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst

Mr Leonard added: “We look forward to building on this initial transaction as we continue to expand our supply network.”

BP8 rose 25% after the news and is now trading around 0.2cps.

Join the discussion: See what HotCopper users are saying about BP Global and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

The agreements – secured through global tool manufacturer Positec – provide Stealth with exclusive selling rights across all market channels for 5 years in the case of Wesco and Harden Hand Tools, alongside a 3-year term for CAT Power Tools.

This will be done through Stealth’s multiple retail channels, which include company owned stores, reseller stores in trade and retail – including network licensee member stores, B2B sales contact centres and field sales representatives, and online sales channels.

Managing director and CEO Mike Arnold said the agreement marked a ‘game-changing’ milestone for Stealth, particularly within the framework of its FY28 growth plan.

“Securing the exclusive distribution rights for these leading brands highlights our commitment to delivering high-quality products, greater value, and enhanced experiences to our customers, while strengthening our market position and accelerating our FY28 growth ambitions,” he said.

“Annual contract purchasing commitments are set to increase year-on-year as we penetrate markets and channels.

“By the FY28 period, commitments across the three contracts, extrapolated into wholesale-level sales guidance based on projected sell-through, are expected to exceed $30 million, with strong margin contributions above 40%, excluding additional margins from company-owned retail stores.”

The company’s revenue target – according to the FY28 plan – is $300 million.

At 16:40 AEDT, shares in Stealth were trading at 73 cents – a rise of 15.87% since the market opened.

Join the discussion: See what HotCopper users are saying about Stealth and be part of the conversations that move the markets.

According to the agreement, Alexso will distribute Maxigesic Rapid tablets (also known as Combogesic) within the US market – the world’s largest for pharmaceuticals – with this news coming only months after AFT gained approval for the drug’s release.

Maxigesic Rapid tablets use a combination of paracetamol and ibuprofen to treat mild to medium pain, and were approved for release on the US market by the country’s Food and Drug Administration (FDA) in March.

AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said the agreement with Alexso represented an important step for the company.

“We are delighted to announce our partnership with Alexso, an established pharmaceutical distribution company which prioritizes non-opioid pain management solutions,” he said.

“We are pleased to be launching our second patented pharmaceutical into the United States market, which we anticipate will occur during this financial year.”

AFT will also continue negotiations with other distributors to target for additional, specific market channels in the United States.

AFT has been trading at $2.80 cents.